90 related articles for article (PubMed ID: 37654003)
1. Evolutionarily conserved resistance to phagocytosis observed in melanoma cells is insensitive to upregulation of pro-phagocytic signals and to CD47 blockade.
Anderson KL; Snyder KM; Ito D; Lins DC; Mills LJ; Weiskopf K; Ring NG; Ring AM; Shimizu Y; Mescher MF; Weissman IL; Modiano JF
Melanoma Res; 2020 Apr; 30(2):147-158. PubMed ID: 31205227
[TBL] [Abstract][Full Text] [Related]
2. Targeting tumor cell-to-macrophage communication by blocking Vtn-C1qbp interaction inhibits tumor progression via enhancing macrophage phagocytosis.
Zhang C; Liu Y; Jiang J; Chen C; Duan Z; Su H; Wang S; Tian B; Shi Y; Xiang R; Luo Y
Theranostics; 2024; 14(7):2757-2776. PubMed ID: 38773982
[No Abstract] [Full Text] [Related]
3. ZBTB28 inhibits breast cancer by activating IFNAR and dual blocking CD24 and CD47 to enhance macrophages phagocytosis.
Li L; Gong Y; Tang J; Yan C; Li L; Peng W; Cheng Z; Yu R; Xiang Q; Deng C; Mu J; Xia J; Luo X; Wu Y; Xiang T
Cell Mol Life Sci; 2022 Jan; 79(2):83. PubMed ID: 35048182
[TBL] [Abstract][Full Text] [Related]
4. Symptomatic leptomeningeal carcinomatosis: a rare presentation of chronic lymphocytic leukaemia relapse.
Batayneh O; Lin A; Abu-Jaradeh O; Wu P; Villamar MF; Sharma P
BMJ Case Rep; 2022 Jun; 15(6):. PubMed ID: 35675961
[TBL] [Abstract][Full Text] [Related]
5. VISTA drives macrophages towards a pro-tumoral phenotype that promotes cancer cell phagocytosis yet down-regulates T cell responses.
Lin Y; Choukrani G; Dubbel L; Rockstein L; Freile JA; Qi Y; Wiersma V; Zhang H; Koch KW; Ammatuna E; Schuringa JJ; van Meerten T; Huls G; Bremer E
Exp Hematol Oncol; 2024 Mar; 13(1):35. PubMed ID: 38553748
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of the efficacy of an antibody to human SIRPα for cancer immunotherapy in humanized mouse models.
Saito Y; Iida-Norita R; Afroj T; Refaat A; Hazama D; Komori S; Ohata S; Takai T; Oduori OS; Kotani T; Funakoshi Y; Koma YI; Murata Y; Yakushijin K; Matsuoka H; Minami H; Yokozaki H; Manz MG; Matozaki T
Front Immunol; 2023; 14():1294814. PubMed ID: 38162643
[TBL] [Abstract][Full Text] [Related]
7. Targeting the GPI transamidase subunit GPAA1 abrogates the CD24 immune checkpoint in ovarian cancer.
Mishra AK; Ye T; Banday S; Thakare RP; Su CT; Pham NNH; Ali A; Kulshreshtha A; Chowdhury SR; Simone TM; Hu K; Zhu LJ; Eisenhaber B; Deibler SK; Simin K; Thompson PR; Kelliher MA; Eisenhaber F; Malonia SK; Green MR
Cell Rep; 2024 Apr; 43(4):114041. PubMed ID: 38573857
[TBL] [Abstract][Full Text] [Related]
8. Engineered CD47 protects T cells for enhanced antitumour immunity.
Yamada-Hunter SA; Theruvath J; McIntosh BJ; Freitas KA; Lin F; Radosevich MT; Leruste A; Dhingra S; Martinez-Velez N; Xu P; Huang J; Delaidelli A; Desai MH; Good Z; Polak R; May A; Labanieh L; Bjelajac J; Murty T; Ehlinger Z; Mount CW; Chen Y; Heitzeneder S; Marjon KD; Banuelos A; Khan O; Wasserman SL; Spiegel JY; Fernandez-Pol S; Kuo CJ; Sorensen PH; Monje M; Majzner RG; Weissman IL; Sahaf B; Sotillo E; Cochran JR; Mackall CL
Nature; 2024 May; ():. PubMed ID: 38750365
[TBL] [Abstract][Full Text] [Related]
9. BNIP3 modulates the interface between B16-F10 melanoma cells and immune cells.
Romano E; Rufo N; Korf H; Mathieu C; Garg AD; Agostinis P
Oncotarget; 2018 Apr; 9(25):17631-17644. PubMed ID: 29707136
[TBL] [Abstract][Full Text] [Related]
10. Feasibly of CD24/CD11b as a Screening Test for Hematological Malignancies.
Shapira S; Kazanov D; Mdah F; Yaakobi H; Herishanu Y; Perry C; Avivi I; Itchaki G; Shacham-Abulafia A; Raanani P; Hay-Levy M; Aiger G; Mashiah J; Lev-Ari S; Arber N
J Pers Med; 2021 Jul; 11(8):. PubMed ID: 34442367
[TBL] [Abstract][Full Text] [Related]
11. Differential expression, localization and activity of MARCKS between mantle cell lymphoma and chronic lymphocytic leukemia.
Vargova J; Vargova K; Dusilkova N; Kulvait V; Pospisil V; Zavadil J; Trneny M; Klener P; Stopka T
Blood Cancer J; 2016 Sep; 6(9):e475. PubMed ID: 27662204
[No Abstract] [Full Text] [Related]
12. Surprising magic of CD24 beyond cancer.
Wang H; Shi P; Shi X; Lv Y; Xie H; Zhao H
Front Immunol; 2023; 14():1334922. PubMed ID: 38313430
[TBL] [Abstract][Full Text] [Related]
13. Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia.
Aroldi A; Mauri M; Ramazzotti D; Villa M; Malighetti F; Crippa V; Cocito F; Borella C; Bossi E; Steidl C; Scollo C; Voena C; Chiarle R; Mologni L; Piazza R; Gambacorti-Passerini C
J Cell Mol Med; 2023 Oct; 27(20):3053-3064. PubMed ID: 37654003
[TBL] [Abstract][Full Text] [Related]
14. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
15. Empowering macrophages: the cancer fighters within the tumour microenvironment in mantle cell lymphoma.
Nylund P; Nikkarinen A; Ek S; Glimelius I
Front Immunol; 2024; 15():1373269. PubMed ID: 38566987
[TBL] [Abstract][Full Text] [Related]
16. Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages.
Zeller T; Lutz S; Münnich IA; Windisch R; Hilger P; Herold T; Tahiri N; Banck JC; Weigert O; Moosmann A; von Bergwelt-Baildon M; Flamann C; Bruns H; Wichmann C; Baumann N; Valerius T; Schewe DM; Peipp M; Rösner T; Humpe A; Kellner C
Front Immunol; 2022; 13():929339. PubMed ID: 36389667
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
